Zobrazeno 1 - 10
of 26
pro vyhledávání: ''
Autor:
Félix López Cadenas, Laura Mezquita, María A Amores Martín, Roberto A. Escala-Cornejo, Luis Figuero-Pérez, Juan Jesús Cruz Hernández, Felipe Gómez-Caminero López, María Del Rosario Vidal Tocino, Alejandro Olivares-Hernández, Lorena Bellido Hernández
Publikováno v:
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine, Vol 2021 (2021)
Case Reports in Oncological Medicine, Vol 2021 (2021)
Background. Immunotherapy represents one of the fundamental treatments in the management of some types of cancer, especially malignant melanoma. Toxicity derived from increased immune system activity can manifest in multiple organs and systems. We pr
Autor:
Kaveh Zivari, Deborah Osafehinti
Publikováno v:
Case Reports in Hematology, Vol 2019 (2019)
Case Reports in Hematology
Case Reports in Hematology
Lenalidomide, a synthetic derivation of thalidomide, in recent years, has been the backbone of multiple myeloma treatment leading to improved survival. Common adverse effects from lenalidomide-based regimens include hypertension, heart disease, and v
Publikováno v:
Case Reports in Otolaryngology, Vol 2020 (2020)
Case Reports in Otolaryngology
Case Reports in Otolaryngology
Drug-induced epithelial hemorrhage of the endolarynx is an unusual etiology of hemoptysis. We present a case of hemoptysis in a young female patient undergoing treatment for metastatic breast cancer with trastuzumab emtansine. Though previously assoc
Publikováno v:
Case Reports in Oncological Medicine, Vol 2019 (2019)
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine
Durvalumab is a therapeutic monoclonal antibody that blocks the checkpoint inhibitor, programmed death ligand 1 (PD-L1), resulting in T-cell activation and an antitumor response. Durvalumab is approved for patients with unresectable stage III non-sma
Publikováno v:
Case Reports in Oncological Medicine, Vol 2021 (2021)
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine
Background. The role of immunotherapy continues to evolve across both solid and hematologic malignancies. However, while use of immunotherapy has increased via the advent of checkpoint inhibition, chimeric antigen receptors, and vaccines against mali
Publikováno v:
Case Reports in Hematology, Vol 2021 (2021)
Case Reports in Hematology
Case Reports in Hematology
Hematological malignancies with a BCR-JAK2 rearrangement have been described only sporadically in the literature over the last three decades. Although most patients suffer from a chronic myeloid neoplasm with marked eosinophilia, the clinical present
Autor:
Solomon A. Graf, Daniel Y Wu, Robert E. Richard, Nicholas Burwick, Craig O'Brien, Thomas R. Chauncey, Heather Klocke, Zhao Ming Dong
Publikováno v:
Case Reports in Hematology, Vol 2020 (2020)
Case Reports in Hematology
Case Reports in Hematology
T/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS) is an uncommon and aggressive leukemia without well-established treatment guidelines, particularly when relapsed. Venetoclax plus a hypomethylating agent offers a promising o
Publikováno v:
Case Reports in Oncological Medicine, Vol 2020 (2020)
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine
A 63-year-old woman was admitted to our institution for severe pain in her right lower abdomen caused by the perforation of cecal cancer. She underwent emergency surgery, from which she was diagnosed with cecal carcinoma with liver, lung, and lymph n
Publikováno v:
Case Reports in Hematology
Case Reports in Hematology, Vol 2018 (2018)
Case Reports in Hematology, Vol 2018 (2018)
Drug-induced thrombotic microangiopathies (DTMAs) are increasingly being recognized as an important category of thrombotic microangiopathies (TMAs). Cancer therapeutic agents including proteasome inhibitors (PIs) are among the most common medications
Autor:
Nicolas Schönfeld, Sven Jungmann, Beate Rehbock, Wolf-Dieter Ludwig, Torsten-Gerriet Blum, Torsten T. Bauer, C Großwendt, Christian Boch, Sergej Griff, Alexander Schmittel
Publikováno v:
Case Reports in Oncological Medicine, Vol 2017 (2017)
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine
We present a 74-year-old male with nonspecific interstitial pneumonia (NSIP) during treatment with ibrutinib for mantle cell lymphoma. Previously, the patient had received six cycles of bendamustine and rituximab and six cycles of R-CHOP, followed by